Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn
About

News

N American healthcare plays standing strong in face of ESG risks

Lex Hall  |  10 Jan 2020Text size  Decrease  Increase  |  
Email to Friend

Sustainable investing is becoming a hallmark of what it means to be a quality company in the 21st century, and a new Morningstar report identifies which big name health companies are inoculated against ESG risks.

Sustainable or responsible investing has become shorthand for the increasingly ubiquitous initialism “ESG”, which refers to a company’s ability to address environmental, social and governance concerns.

For the individual investor trying to construct a winning portfolio, it’s not simply a matter of avoiding so-called sin stocks or holding companies that reflect one’s values, says Morningstar’s head of sustainability research Jon Hale.  

It’s about finding companies that perform well on the financially material ESG-related issues that affect their businesses and avoiding those that fail to tackle these issues effectively.

Companies that address ESG risks most effectively also tend to be high-quality companies, Hale says.

“For a transportation company - an airline, for example - the biggest ESG concerns may be carbon emissions, safety, and human capital.

“For a social-media company, material ESG issues include data privacy and security, content governance, and anticompetitive practices.

“My view is that strong ESG performance is becoming a hallmark of what it means to be a quality company in the 21st century. Quality companies tend to turn their competitive advantages into steady long-term growth.”

With that in mind, Morningstar has released its first ESG report into the healthcare industry.

Morningstar’s January 2020 Healthcare Observer examines branded biotech and pharmaceutical companies, which have been at the centre of controversy over high prices and product safety issues as well as blurred ethical lines relating to areas such as intellectual property, delayed generic entry, and collusion.

According to the Observer, the following five names stand out as being both undervalued and less exposed to ESG-related risk:

At the other end of the scale, Johnson & Johnson (JNJ) and Eli Lilly (LLY) look the least compelling.

Undervalued pharma and biotech companies with lower ESG risk

Undervalued pharma and biotech firms with lower ESG risk

Source: Morningstar. Pricing data as of Jan. 2, 2020

Following are some of the key findings of the report.

Best Ideas Roche and BioMarin face lowest ESG risk

Overall, Morningstar sees the lowest exposure to ESG-related risks at Best Ideas Roche and BioMarin, and both names stand out as undervalued. Roche's diagnostics diversification, global pricing strategies, and focus on severe diseases lower pricing and litigation risk.

In addition, Roche's current US biosimilar pressure (included in our base case) already factors in much of the potential headwind from international benchmark pricing, which could be tested in Medicare Part B.

BioMarin's global pricing strategy for its rare-disease drugs as well as the serious nature of these conditions limit future pricing and litigation risk, despite high price tags, and Medicare exposure is minimal.

Sanofi and Gilead attractive on valuation and ESG risk

Other firms, including Sanofi and Gilead, perform well on ESG measures and look undervalued. Gilead's limited US price increases for its HIV portfolio have helped the firm avoid massive price discrepancies with other markets.

Sanofi's diversified business and rare-disease portfolio limit exposure to US pricing reform. Pfizer also performs well, but exposure to Medicare Part D oncology therapies (expensive medicines that also generally see significant price increases) gives exposure to potential US pricing reform.

Johnson & Johnson, Lilly least compelling

J&J and Lilly look the least compelling to us, based on litigation risk and valuation, while AbbVie and Biogen look undervalued despite high pricing risk.

J&J and Lilly both have portfolios focused on chronic, less severe diseases, a history of significant litigation expenses, and fully-valued portfolios and pipelines.

Biogen's multiple sclerosis portfolio and AbbVie's immunology therapies have built up the largest US price discrepancies versus other developed markets, and both have high US exposure; however, current valuations don't appear to give enough credit to their newer products and pipelines.

ESG report card

Key considerations when evaluating healthcare companies include:

  • Access to basic services
  • How drug firms are exposed to pricing risk, and how they manage responsibility to ensure patients have access to innovative therapies
  • Product governance
  • How drug firms manage responsibility to patients and other stakeholders, including quality management, marketing, and long-term safety
  • Business ethics
  • How drug firms manage marketing, competition and intellectual property issues

 

is content editor for Morningstar Australia

Any Morningstar ratings/recommendations contained in this report are based on the full research report available from Morningstar.

© 2020 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. This information is to be used for personal, non-commercial purposes only. No reproduction is permitted without the prior written consent of Morningstar. Any general advice or 'class service' have been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), or its Authorised Representatives, and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. Please refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/s/fsg.pdf. Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Past performance does not necessarily indicate a financial product's future performance. To obtain advice tailored to your situation, contact a licensed financial adviser. Some material is copyright and published under licence from ASX Operations Pty Ltd ACN 004 523 782. The article is current as at date of publication.

Email To Friend